These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24985059)

  • 21. Prevalence of BRAF and NRAS mutations in fast-growing melanomas.
    Nagore E; Hacker E; Martorell-Calatayud A; Traves V; Guillen C; Hayward NK; Whiteman D
    Pigment Cell Melanoma Res; 2013 May; 26(3):429-31. PubMed ID: 23448684
    [No Abstract]   [Full Text] [Related]  

  • 22. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
    Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
    Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crystal structure of NRAS Q61K with a ligand-induced pocket near switch II.
    Gebregiworgis T; Chan JY; Kuntz DA; Privé GG; Marshall CB; Ikura M
    Eur J Cell Biol; 2024 Jun; 103(2):151414. PubMed ID: 38640594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Refinement of the endogenous epitope tagging technology allows the identification of a novel NRAS binding partner in melanoma.
    Alon M; Emmanuel R; Qutob N; Bakhman A; Peshti V; Brodezki A; Bassan D; Kosloff M; Samuels Y
    Pigment Cell Melanoma Res; 2018 Sep; 31(5):641-648. PubMed ID: 29665313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).
    Sacco E; Spinelli M; Vanoni M
    Expert Opin Ther Pat; 2012 Nov; 22(11):1263-87. PubMed ID: 23009088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
    Mar VJ; Wong SQ; Li J; Scolyer RA; McLean C; Papenfuss AT; Tothill RW; Kakavand H; Mann GJ; Thompson JF; Behren A; Cebon JS; Wolfe R; Kelly JW; Dobrovic A; McArthur GA
    Clin Cancer Res; 2013 Sep; 19(17):4589-98. PubMed ID: 23833303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Signal transduction elements of TC21, an oncogenic member of the R-Ras subfamily of GTP-binding proteins.
    Movilla N; Crespo P; Bustelo XR
    Oncogene; 1999 Oct; 18(43):5860-9. PubMed ID: 10557073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional status and relationships of melanocortin 1 receptor signaling to the cAMP and extracellular signal-regulated protein kinases 1 and 2 pathways in human melanoma cells.
    Herraiz C; Journé F; Ghanem G; Jiménez-Cervantes C; García-Borrón JC
    Int J Biochem Cell Biol; 2012 Dec; 44(12):2244-52. PubMed ID: 23000456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug combo shows promise in NRAS-mutant melanoma.
    Cancer Discov; 2014 Aug; 4(8):OF2. PubMed ID: 25092757
    [No Abstract]   [Full Text] [Related]  

  • 30. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
    Ogawa K; Sun C; Horii A
    Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RaLP, a new member of the Src homology and collagen family, regulates cell migration and tumor growth of metastatic melanomas.
    Fagiani E; Giardina G; Luzi L; Cesaroni M; Quarto M; Capra M; Germano G; Bono M; Capillo M; Pelicci P; Lanfrancone L
    Cancer Res; 2007 Apr; 67(7):3064-73. PubMed ID: 17409413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NRAS mutations in de novo acute leukemia: prevalence and clinical significance.
    Dunna NR; Vuree S; Anuradha C; Sailaja K; Surekha D; Digumarti RR; Rao VR; Yadav SK; Reddy R; Vishnupriya S
    Indian J Biochem Biophys; 2014 Jun; 51(3):207-10. PubMed ID: 25204082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?
    Passeron T; Lacour JP; Allegra M; Ségalen C; Deville A; Thyss A; Giacchero D; Ortonne JP; Bertolotto C; Ballotti R; Bahadoran P
    Exp Dermatol; 2011 Dec; 20(12):1030-2. PubMed ID: 22092579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic alterations in signaling pathways in melanoma.
    Haluska FG; Tsao H; Wu H; Haluska FS; Lazar A; Goel V
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2301s-2307s. PubMed ID: 16609049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma.
    Ilie M; Long-Mira E; Funck-Brentano E; Lassalle S; Butori C; Lespinet-Fabre V; Bordone O; Gay A; Zahaf K; Poissonnet G; Lacour JP; Bahadoran P; Ballotti R; Gros A; Dutriaux C; Saiag P; Merlio JP; Vergier B; Emile JF; Hofman V; Hofman P
    J Am Acad Dermatol; 2015 May; 72(5):786-93. PubMed ID: 25659223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.
    Haluska F; Pemberton T; Ibrahim N; Kalinsky K
    Semin Oncol; 2007 Dec; 34(6):546-54. PubMed ID: 18083378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The K-Ras, N-Ras, and H-Ras Isoforms: Unique Conformational Preferences and Implications for Targeting Oncogenic Mutants.
    Parker JA; Mattos C
    Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29038336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calcium channel expression and applicability as targeted therapies in melanoma.
    Macià A; Herreros J; Martí RM; Cantí C
    Biomed Res Int; 2015; 2015():587135. PubMed ID: 25710007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Approaches to RAS Mutation.
    Scott AJ; Lieu CH; Messersmith WA
    Cancer J; 2016; 22(3):165-74. PubMed ID: 27341593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.